



High-dose ICS

—●— Phase 2b: placebo/dupilumab —●— Phase 2b: dupilumab/dupilumab
 —●— QUEST: placebo/dupilumab —●— QUEST: dupilumab/dupilumab


(A) Exposed population



(B) ≥ 150 eosinophils/ μ L at PSBL



(C) ≥ 300 eosinophils/ μ L at PSBL



(D) FeNO ≥ 25 ppb at PSBL

